Although GIP receptor agonists are still under clinical trial, GLP-1 receptor agonists have been widely used for the therapy of patients with type 2 diabetes as well as patients with obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.